See the DrugPatentWatch profile for Tresiba
The generic release date for Tresiba (insulin degludec) is currently unknown and is dependent on patent expiry and potential legal challenges. DrugPatentWatch.com tracks patent information and potential generic entry dates for various medications.
When is Tresiba's Patent Expected to Expire?
Tresiba is protected by several patents. The earliest anticipated expiration dates for some of these patents could fall around 2026, but this is subject to change. Patent expiration dates can be complex and may be extended through various legal mechanisms, such as patent term extensions or adjustments due to regulatory delays.
What Could Delay Generic Tresiba?
The introduction of generic versions of Tresiba can be delayed by several factors. Patent litigation is a common hurdle, where the innovator company may sue generic manufacturers for patent infringement. If these lawsuits are successful, they can prevent generic entry for a significant period. Additionally, the Food and Drug Administration (FDA) approval process for generics itself takes time.
How is Tresiba Different from Other Insulins?
Tresiba is a long-acting basal insulin with a unique ultra-long duration of action, lasting for more than 42 hours [1]. This allows for greater dosing flexibility compared to other basal insulins, which typically have durations of around 24 hours. It achieves its prolonged effect through its specific chemical structure and formulation, which involves fatty acid chains attached to the insulin molecule [2].
Who Makes Tresiba?
Tresiba is manufactured by Novo Nordisk.
What are the Latest Developments in Tresiba Litigation?
Information regarding specific patent litigation surrounding Tresiba would be available through legal databases and patent trackers. These disputes can impact the timeline for generic availability. For detailed insights into patent status and litigation, resources like DrugPatentWatch.com are valuable [3].
Can Biosimilars of Tresiba Be Developed?
As Tresiba is a biologic (insulin), biosimilars, rather than generics, would be developed. The pathway for biosimilar approval is governed by specific regulations, and their entry into the market also depends on patent protections and potential litigation.
What is the Cost of Tresiba?
The cost of Tresiba is typically high, as it is a branded biologic medication. Generic or biosimilar versions, once available, are generally expected to be priced lower, increasing access for patients.
Sources
1. https://www.novonordisk.com/patients/diabetes/our-insulin-portfolio/tresiba.html
2. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3785733/
3. https://drugpatentwatch.com/